Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
Big Pharma expanding India GCCs, taps into talent in IT, AI, and analytics
Big Pharma’s global capability centers (GCCs) in India are evolving well beyond being just “cost efficiency outposts” and transitioning, in some cases, to emerge as centers of excellence (CoEs) unlocking new technological advancements and leveraging data insights.
Key Takeaways
Leaders from AZ, BMS, Novo Nordisk, Takeda & Regeneron discuss how things are evolving at their global capability centers (GCCs) in India
